[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.119.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,821
Citations 0
Viewpoint
Vital Directions from the National Academy of Medicine
October 25, 2016

Innovation in Medicine and Device Development, Regulatory Review, and Use of Clinical Advances

Author Affiliations
  • 1Flagship Ventures, Cambridge, Massachusetts
  • 2Merck and Co Inc, Kenilworth, New Jersey
  • 3National Health Council, Washington, DC
  • 4Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles
  • 5Anthem Inc, Indianapolis, Indiana
JAMA. 2016;316(16):1671-1672. doi:10.1001/jama.2016.12486

Breakthrough advances in the understanding of fundamental biology and the dawn of an era of precision medicine coupled with access to “big data” and research conducted in clinical care settings herald a new age of innovation for drug discovery and devices with the promise of improved health. However, these clinical advances need to be both affordable and accessible. There are competing national priorities for investment, including education and other social determinants of health. To realize the health benefits deriving from new scientific insights, increased discovery and translation of innovation through more efficient clinical trials and rapid deployment of effective advances to appropriate patient populations will be essential.

First Page Preview View Large
First page PDF preview
First page PDF preview
×